Tue, Oct 21, 2014, 10:40 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

IntelliCell BioSciences, Inc. Message Board

  • surfntravel surfntravel Nov 25, 2013 10:23 AM Flag

    Will Japan overtake US in stem cell reasearch? Politicians need to step up their game in the US.

    Fast track non invasive no manipulating procedures like SVFC would be a step in the right direction. Safety through medical oversight but let the research run.

    "reported that on November 20, 2013, the Japanese legislature (Diet) approved new legislation targeted at regenerative medicine therapies. The Regenerative Medicine Law directs the Ministry of Health, Labour and Welfare (MHLW) to adopt new procedures and rules that would accelerate the clinical development of regenerative medicine and cell therapies. The Japanese Pharmaceutical Affairs Law (J-PAL) will now become the Pharmaceuticals and Medical Devices Act that will include a new branch for Regenerative Medicine Products. Regenerative Medicine Products will be regulated on a Fast Track process that focuses primarily on product safety."

    “The legislation has been designed to benefit patients and developers alike to bring innovative, cost-effective therapies to market in a risk-adjusted manner, and enable Japan to capitalize on the economic opportunity represented by regenerative medicine,” “Multiple investigator-initiated and funded studies using Cell Therapy have been completed at leading hospitals in Japan, and more are underway or are in the planning stages. We look forward to providing more details on the impact of the legislation as they become available.”

 
SVFC
0.0004+0.0001(+33.33%)Oct 21 3:57 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.